Prasanna Bhanshe
Navi Mumbai, MH, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Clinical Relevance of Genomics Defined WHO5 Subtypes of Pediatric B-ALL in the Context of Measurable Residual Disease-Directed Risk-Based Therapy.
Journal: JCO global oncology
Published: September 03, 2026
Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML.
Journal: JCO global oncology
Published: February 20, 2026
Acute myeloid leukaemia (AML) harbouring KMT2A-PTD: should it be considered as a myelodysplasia-related abnormality?
Journal: Journal of clinical pathology
Published: October 01, 2025
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
Journal: Leukemia
Published: August 26, 2020
Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1.
Journal: Leukemia & lymphoma
Published: August 08, 2020
A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1.
Journal: Blood cancer journal
Published: July 11, 2019
Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context.
Journal: Frontiers in oncology
Published: March 05, 2019
Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.
Journal: Oncotarget
Published: February 08, 2019
Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia.
Journal: Oncotarget
Published: April 16, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026